Skip to main content
. Author manuscript; available in PMC: 2016 Mar 18.
Published in final edited form as: Leuk Lymphoma. 2015 Oct 12;57(3):666–675. doi: 10.3109/10428194.2015.1071488

Figure 3.

Figure 3

Disease-free survival (DFS) and overall survival (OS) by route of busulfan administration. Survival outcomes were similar for patients receiving either intravenous (i.v.) or oral busulfan [DFS i.v. busulfan HR 1.1 (95% CI 0.59, 2.08), p = 0.76; OS i.v. busulfan HR 1.24 (95% CI 0.63, 2.42), p = 0.534].